key: cord-0799571-llf5e2ls authors: Sziemel, Agnieszka M; Hwa, Shi-Hsia; Sigal, Alex; Tyson, Grace; Logan, Nicola; Willett, Brian J.; Durcan, Peter J title: Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351 date: 2021-04-12 journal: bioRxiv DOI: 10.1101/2021.04.11.439360 sha: c493378be643fa8cddf643b66f8a9949d6bc1c8c doc_id: 799571 cord_uid: llf5e2ls The pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. During the years of 2020-2021, millions of humans have died due to SARS-CoV-2 infection and severe economic damage to the global economy has occurred. Unprecedented rapid investments in vaccine development have been made to counter the spread of SARS-CoV-2 among humans. While vaccines are a key pillar of modern medicine, SARS-CoV-2 has mutated as it spread among humans. Vaccines previously developed and approved by regulators are becoming less effective against new variants. One variant of SARS-CoV-2 known as B.1.351 that was first reported to be present in South Africa significantly reduces the efficacy of vaccines developed to date. Therapeutic options that work against the B.1.351 variant are therefore urgently needed to counteract reduced vaccine efficacy. We present here the discovery of recombinant alpaca antibodies that neutralise live virus of B.1.351 and other SARS-CoV-2 variants potently. The antibodies described here may be a useful tool for clinicians who are treating patients infected with B.1.351 and other SARS-CoV-2 for which there is currently no known highly effective treatment. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19) 1 . Common clinical features of COVID-19 include pneumonia, fever, cough and myalgia 1, 2 . The World Health Organization on the 11 th of March 2020 declared COVID-19 a global pandemic 3 . Towards the end of February 2021 over 2.5 million people had died due to COVID-19 4 . Such a high death toll highlights the need for both effective vaccines and therapeutics to be developed so that human lives can be saved. Vaccines for COVID-19 prevention have been developed at an unprecedent rate and data from Phase 3 trials showed excellent results at preventing severe COVID-19 disease and reducing deaths 5, 6 . However, since these promising vaccine results were released, variants of SARS-CoV-2 have emerged that display an ability to escape neutralization from serum of vaccinated individuals 7, 8 . The aforementioned in vitro results are suggestive that recently developed vaccines may be less effective against new variants of SARS-CoV-2 and indeed such reduced efficacy has been recently reported in clinical trials 7 . One particular SARS-CoV-2 variant of concern is the B.1.351, a variant that was originally identified in South Africa and which is now the dominant lineage in circulation within the country 9 Currently, there is no highly effective treatment for COVID-19. At present, the most successful therapeutic option available to clinicians for the treatment of COVID-19 is the steroid dexamethasone which can decrease deaths in patients who are under invasive mechanical ventilation by approximately 30% compared to standard care 10 . Other treatment avenues being explored include: repurposed antiviral drugs such as the nucleoside analogues favipiravir (Toyama Chemical) and remdesivir (Gilead) (reviewed in 11 ); biological productbased therapies including the IL6-receptor agonists tocilizumab (Roche) 12 and sarilumab (Sanofi) 13 ; and monoclonal antibody cocktails such as casirivimab (Regeneron) 14 and bamlanivimab (Lilly) 15 . Chemical compounds for treatment of COVID-19 merit serious investigation, however, their development time to reach the clinic may take many years. An alternative to chemical compounds for COVID-19 treatment are biological products such as antibodies that can bind to the virus and neutralise it, thereby stopping it from infecting cells and producing more viral particles in the infected patient. Indeed, some human antibodies have already been developed and tested in a clinical setting in relation to COVID-19 15 . In light of such a global health need, we investigated recombinant alpaca antibodies, commonly known as "nanobodies", as novel therapeutics for the neutralisation of SARS-CoV- In this study, we hypothesized that nanobodies targeting the SARS-CoV-2 spike glycoprotein may offer a novel approach to therapy for COVID-19 as has been suggested by others 24, 25 . Here, we report the development of a collection of nanobodies that neutralise SARS-CoV-2 variants potently, including one nanobody that neutralises the variant of concern, B.1.351. A single alpaca was immunized with recombinant S1 subunit of the SARS-CoV-2 spike glycoprotein. Sera were collected pre-immunization, and at weeks 2, 4 and 8 postimmunization were and were tested for ability to neutralise live virus of the SARS-CoV-2-CVR-GLA-1 isolate of SARS-CoV-2 26 . Plaque reduction assays demonstrated the development of a neutralising antibody titre of 560 by 8 weeks post-immunisation ( Figure 1A ,B&C). Following the completion of the immunization protocol, 8 different nanobody sequences that bound to the recombinant S1 protein were isolated from the immune library via phage neutralised efficiently by the three nanobodies A1, C3 and C9, recapitulating the findings with live virus. The E484K mutation markedly reduced neutralisation by nanobodies C3 and C9, but did not affect neutralisation by A1 (Fig.4B ). In contrast, the N501Y and P681H mutations had no effect on sensitivity to neutralisation by either A1, C3 or C9. These data suggest that the A1 nanobody recognizes an epitope that is distinct from the epitopes recognised by C3 and C9, an epitope that is affected by neither the E484K nor N501Y mutations (Fig. 4B) and which may present a novel target for SARS-CoV-2 therapeutics. The COVID-19 pandemic has resulted in millions of deaths and severe economic damage to all countries in the world. The causative agent of COVID-19 is a highly infectious novel human coronavirus, SARS-CoV-2 2 . As a novel emerging virus, SARS-CoV-2 presents a unique threat to the naïve host, the immune system requiring a period of time to develop a virus-specific immune response. If the host is overwhelmed by the virus before a specific immune response has had time to develop, a severe, often fatal disease may ensue. Global health systems have struggled to deal effectively with SARS-CoV-2 infections as there are currently no highly effective therapeutics. Such a lack of treatment results in patients frequently overwhelming the specialist respiratory care facilities that are needed to manage COVID-19 patients who frequently present to hospital with dyspnea 1,2 . In light of the challenges that the emergence of SARS-CoV-2 has placed on the global healthcare system, we provide evidence that a biological-based therapy for COVID-19 that revolves around the use of nanobodies may be useful. The rationale behind this concept is that nanobodies are structurally different to human antibodies in that they contain only a heavy chain antigen binding component compared to the heavy and light chain antigen binding component of human antibodies 28 . Nanobodies can bind with a high affinity to their target antigen 29 . Due to their heavy chain only structure, they can target epitopes on viral antigens that are inaccessible to conventional antibodies 28 . They display high thermal and chemical stability 28 and hence are well-suited to use as therapeutic agents. Given that nanobodies can target epitopes that are distinct from those targeted by conventional antibodies, it is reasonable to assume that SARS-CoV-2 variants in the general population have not been placed under any selective pressure to escape neutralisation by antibodies targeting such epitopes. Hence, it should be possible to develop nanobodies that recognize novel epitopes that retain broad neutralising activity. In the work presented here we identified nanobodies with potent neutralizing activity against SARS-CoV-2, with IC50 values of below 3nM. One monovalent nanobody, C9, had low picomolar IC50 values against two different SARS-CoV-2 variants but was not effective against These data may indicate that the A1 nanobody targets an epitope that is conserved between variants. Further, it is possible that the epitope recognised by A1 may not tolerate mutation, forming a structure that is essential to the function of the spike glycoprotein. Similarly, the epitope may not be under selective pressure in the general population as it is inaccessible to conventional antibodies. Clinical trials have reported that at least one vaccine currently being used globally for COVID-19 prevention has a reduced efficacy in preventing COVID-19 disease mediated by infection with the B.1.351 variant 7 . Due to the lack of current treatment options available to clinicians for the treatment of COVID-19 the nanobodies reported here may be a useful tool for them to use in order to save patient lives. One adult male alpaca was immunized subcutaneously over a 12-week period at the following time points; week 0, 2, 4, 8, 10 and 12. For the first immunization, 250ug of recombinant S1 protein (comprising amino acids 1-674 of subunit 1 of the spike glycoprotein, Native Antigen Company, UK) was used followed by 200ug in all subsequent immunizations. Gerbu Fama (GERBU Biotechnik, Germany) was the adjuvant used. A volume of 20ml of blood was drawn at all time points and collected into serum blood collection tubes. On week 13 an additional 80 ml of blood was collected into EDTA-coated blood collection tubes. All animal work was approved by the Afrobodies Institutional ethics and animal care committee. Heavy chain only alpaca antibody library creation was done largely according to the protocol of Pardon et al 34 . Briefly, PBMCS were isolated from 80ml of Week 13 blood using 50ml Accuspin tubes (Sigma Aldrich) and the recommended protocol of the manufacturer was followed. Following PBMC isolation, RNA was isolated from the PBMCS using the Trizol method. Post isolation, RNA was reverse transcribed using the SuperScript IV protocol. Subsequent cloning of the VHH sequences, insertion into phagemid plasmids and library creation was as described previously 34 . Two rounds of panning against the spike 1 antigen was performed followed by selection of 94 individual clones. Testing of recombinant alpaca antibody binding to antigen, isolation of sequences and production of recombinant alpaca antibodies was done as described previously 34 . Stocks of individual nanobodies were disbursed to testing centers in Phosphate Buffered Saline at a concentration of 500ug/ml. Vero E6 F5 cells, which were subcloned from Vero E6 cells, were maintained in DMEM-Glutamax supplemented with 10% fetal bovine serum 26 (Gibco Thermo Fisher Scientific). virus was propagated and titred as described 35 . After paraformaldehyde fixation, cells were immunostained using a rabbit anti-spike monoclonal antibody (mAb BS-R2B12, GenScript A02058), anti-rabbit IgG peroxidase conjugate, and TrueBlue substrate (Kerafast). Plates were scanned with a 2x objective on a Nikon Ti-E microscope, and foci were counted using a custom script in MATLAB (MathWorks). 50% neutralization titers were calculated in GraphPad Prism 9 by performing a sigmoidal fourparameter logistic curve fit with the bottom parameter constrained to zero, and the top parameter constrained to the average of the no-antibody controls for each respective virus; the "IC50" calculated by Prism was reported as the NT50 for each antibody. Mutations corresponding to those in variants of concern were engineered into the SARS-CoV- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Clinical features of patients infected with 2019 novel coronavirus in Wuhan WHO Director-General's opening remarks at the media briefing on COVID-19 -11 Coronavirus Update (Live): 120,486,601 Cases and 2,666 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein Dexamethasone in Hospitalized Patients with Covid-19 Compounds with Therapeutic Potential against Novel Respiratory Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 Production, characterization and in vitro testing of HBcAg-specific VHH intrabodies Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules In vitro antiviral activity of single domain antibody fragments against poliovirus Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea Evaluation of efficacy and safety of the anti-VWF Nanobody An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera Reduced binding and neutralization of infection-and vaccineinduced antibodies to the B.1.351 (South African) SARS-CoV-2 variant SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma A general protocol for the generation of Nanobodies for structural biology A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo Conflicts of Interest PJD is Co-Founder, Chief Scientific Officer and share holder of Afrobodies Pty Ltd